FDA cites Emergent BioSolutions Baltimore plant for CGMP violations after metal particulates and poor aseptic technique in sterile drugs.
What happened
FDA inspected the Baltimore facility from February 7 to 11, 2022, and from February 14 to 18, 2022. Investigators found damaged tray units used in aseptic processing were linked to metal particulates in sterile drug products, and they observed poor aseptic technique during filling interventions. FDA also said similar deviations were cited in a 2021 inspection and that the company's response was inadequate.
What FDA found
The company did not adequately clean and maintain equipment, and damaged tray units used in aseptic processing caused metal particulates in sterile drug products.
21 CFR 211.67(a) and (b)The company did not establish and follow adequate procedures to prevent microbiological contamination, and investigators saw poor aseptic technique that could breach sterility.
21 CFR 211.113(b)FDA said similar deviations were cited in an April 2021 inspection, so repeated failures showed inadequate executive oversight.
FDA found the quality unit was not fully exercising its authority or responsibilities under CGMP.
What FDA wants
FDA asks the company to respond in writing within 15 working days with corrective action plans, independent reviews of particulate contamination and contamination hazards, and a plan to strengthen quality unit oversight. FDA also strongly recommends engaging a qualified CGMP consultant.
Who should pay attention
- hospitals and patients using sterile injectable drugs from this site
- companies contracting this facility for sterile fill/finish
- quality teams at sterile drug manufacturers with similar tray and aseptic processes
This is a summary. Read the original letter on fda.gov.